Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Air Pollutant Might Be to Blame for NDMA Formation in Metformin: Towa Paper
To read the full story
Related Article
- Towa Develops Analytical Method for Nitrosamine in Antidepressant Duloxetine
March 12, 2024
- Metformin Cancer Risk Acceptable at 1 in 550,000 Patients: NIHS Assessment
October 1, 2020
- Towa, Nichi-Iko Recalling Some Metformin Products over Carcinogen Risks, Follow 2 Makers
September 17, 2020
- Sumitomo Dainippon, Nihon Generic Pulling Some Metformin Products over Carcinogen Risks
April 28, 2020
- Metformin Manufacturers Ordered to Test for Potential Carcinogen Contamination
December 10, 2019
BUSINESS
- Renalys, Japan Kidney Association Join Hands to Develop Innovative Therapies
May 8, 2024
- Santen, Mitsubishi Tanabe to Copromote Alesion Eyelid Cream in Japan
May 8, 2024
- Astellas, Poseida Expand Collab in Off-the-Shelf Cell Therapies for Cancer
May 7, 2024
- Jevtana Supply Crunch amid Demand Spike Already Affecting Patients in Japan
May 7, 2024
- Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
May 2, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…